Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 2, 2019, Pages 353-361

  Vaughn, Byron P ^a   Rank, Kevin M ^a   Khoruts, Alexander ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Clostridium difficile Infection; Fecal Microbiota Transplantation; Inflammatory Bowel Disease; Irritable Bowel Syndrome; Liver Disease; Pathobiome

Indexed keywords

ANTIBIOTIC AGENT;

CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DYSBIOSIS; ENCAPSULATION; FECAL MICROBIOTA TRANSPLANTATION; FREEZE DRYING; GASTROINTESTINAL DISEASE; HEPATIC ENCEPHALOPATHY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; LIVER DISEASE; NONHUMAN; PATIENT SAFETY; REMISSION; REVIEW; TREATMENT FAILURE; ULCERATIVE COLITIS;

EID: 85059191155     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.07.026     Document Type: Review

References (88)

1. Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498 quiz 499.
2. McDonald, L.C., Gerding, D.N., Johnson, S., et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66 (2018), 987–994.
3. Bakken, J.S., Borody, T., Brandt, L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9 (2011), 1044–1049.
4. Khoruts, A., Dicksved, J., Jansson, J.K., et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44 (2010), 354–360.
5. Mukherjee, P.K., Sendid, B., Hoarau, G., et al. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 12 (2015), 77–87.
6. Mirzaei, M.K., Maurice, C.F., Menage a trois in the human gut: interactions between host, bacteria and phages. Nat Rev Microbiol 15 (2017), 397–408.
7. Ramanan, D., Bowcutt, R., Lee, S.C., et al. Helminth infection promotes colonization resistance via type 2 immunity. Science 352 (2016), 608–612.
8. Ishaq, S.L., Sundset, M.A., Crouse, J., et al. High-throughput DNA sequencing of the moose rumen from different geographical locations reveals a core ruminal methanogenic archaeal diversity and a differential ciliate protozoal diversity. Microb Genom, 1, 2015, e000034.
9. Dethlefsen, L., McFall-Ngai, M., Relman, D.A., An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449 (2007), 811–818.
10. Backhed, F., Ley, R.E., Sonnenburg, J.L., et al. Host-bacterial mutualism in the human intestine. Science 307 (2005), 1915–1920.
11. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
12. Borody, T.J., Khoruts, A., Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9 (2012), 88–96.
13. Hamilton, M.J., Weingarden, A.R., Sadowsky, M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 761–767.
14. Youngster, I., Russell, G.H., Pindar, C., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312 (2014), 1772–1778.
15. Kao, D., Roach, B., Silva, M., et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 318 (2017), 1985–1993.
16. Staley, C., Hamilton, M.J., Vaughn, B.P., et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol 112 (2017), 940–947.
17. Khoruts, A., Is fecal microbiota transplantation a temporary patch for treatment of Clostridium difficile infection or a new frontier of therapeutics?. Expert Rev Gastroenterol Hepatol 12 (2018), 435–438.
18. Hoffmann, D., Palumbo, F., Ravel, J., et al. Improving regulation of microbiota transplants. Science 358 (2017), 1390–1391.
19. Staley, C., Kaiser, T., Beura, L.K., et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. Microbiome, 5, 2017, 87.
20. Chung, H., Pamp, S.J., Hill, J.A., et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149 (2012), 1578–1593.
21. Ochman, H., Worobey, M., Kuo, C.H., et al. Evolutionary relationships of wild hominids recapitulated by gut microbial communities. PLoS Biol, 8, 2010, e1000546.
22. Morens, D.M., Folkers, G.K., Fauci, A.S., The challenge of emerging and re-emerging infectious diseases. Nature 430 (2004), 242–249.
23. Eiseman, B., Silen, W., Bascom, G.S., et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44 (1958), 854–859.
24. Persky, S.E., Brandt, L.J., Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 95 (2000), 3283–3285.
25. Aas, J., Gessert, C.E., Bakken, J.S., Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 (2003), 580–585.
26. Cammarota, G., Ianiro, G., Tilg, H., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66 (2017), 569–580.
27. Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109 (2014), 1065–1071.
28. Kakihana, K., Fujioka, Y., Suda, W., et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood 128 (2016), 2083–2088.
29. DeFilipp, Z., Peled, J.U., Li, S., et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2 (2018), 745–753.
30. Woodworth, M.H., Carpentieri, C., Sitchenko, K.L., et al. Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review. Gut Microbes 8 (2017), 225–237.
31. Roberts, T., Stark, D., Harkness, J., et al. Subtype distribution of Blastocystis isolates identified in a Sydney population and pathogenic potential of Blastocystis. Eur J Clin Microbiol Infect Dis 32 (2013), 335–343.
32. Audebert, C., Even, G., Cian, A., et al. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. Sci Rep, 6, 2016, 25255.
33. Krogsgaard, L.R., Engsbro, A.L., Stensvold, C.R., et al. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study. Clin Gastroenterol Hepatol 13 (2015), 507–513 e2.
34. Rossen, N.G., Bart, A., Verhaar, N., et al. Low prevalence of Blastocystis sp. in active ulcerative colitis patients. Eur J Clin Microbiol Infect Dis 34 (2015), 1039–1044.
35. Vrieze, A., Van Nood, E., Holleman, F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (2012), 913–916 e7.
36. Kootte, R.S., Levin, E., Salojarvi, J., et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 26 (2017), 611–619 e6.
37. Ridaura, V.K., Faith, J.J., Rey, F.E., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341, 2013, 1241214.
38. Fischer, M., Kao, D., Kassam, Z., et al. Stool donor body mass index does not affect recipient weight after a single fecal microbiota transplantation for Clostridium difficile infection. Clin Gastroenterol Hepatol 16 (2018), 1351–1353.
39. Alang, N., Kelly, C.R., Weight gain after fecal microbiota transplantation. Open Forum Infect Dis, 2, 2015, ofv004.
40. Fischer, M., Bittar, M., Papa, E., et al. Can you cause inflammatory bowel disease with fecal transplantation? A 31-patient case-series of fecal transplantation using stool from a donor who later developed Crohn's disease. Gut Microbes 8 (2017), 205–207.
41. Blaser, M.J., The theory of disappearing microbiota and the epidemics of chronic diseases. Nat Rev Immunol 17 (2017), 461–463.
42. Millan, B., Park, H., Hotte, N., et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 62 (2016), 1479–1486.
43. Khoruts, A., Sadowsky, M.J., Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 13 (2016), 508–516.
44. Gopalakrishnan, V., Spencer, C.N., Nezi, L., et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359 (2018), 97–103.
45. Matson, V., Fessler, J., Bao, R., et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359 (2018), 104–108.
46. Routy, B., Le Chatelier, E., Derosa, L., et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359 (2018), 91–97.
47. Krezalek, M.A., DeFazio, J., Zaborina, O., et al. The shift of an intestinal “microbiome” to a “pathobiome” governs the course and outcome of sepsis following surgical injury. Shock 45 (2016), 475–482.
48. McClave, S.A., Patel, J., Bhutiani, N., Should fecal microbial transplantation be used in the ICU?. Curr Opin Crit Care 24 (2018), 105–111.
49. Li, Q., Wang, C., Tang, C., et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit Care, 19, 2015, 37.
50. Wurm, P., Spindelboeck, W., Krause, R., et al. Antibiotic-associated apoptotic enterocolitis in the absence of a defined pathogen: the role of intestinal microbiota depletion. Crit Care Med 45 (2017), e600–e606.
51. Wei, Y., Yang, J., Wang, J., et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care, 20, 2016, 332.
52. Li, Q., Wang, C., Tang, C., et al. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. Am J Gastroenterol 109 (2014), 1832–1834.
53. Weingarden, A.R., Hamilton, M.J., Sadowsky, M.J., et al. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol 47 (2013), 735–737.
54. Khoruts, A., Hippen, K.L., Lemire, A.M., et al. Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. Transl Res 179 (2017), 116–125.
55. Shono, Y., Docampo, M.D., Peled, J.U., et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med, 8, 2016, 339ra71.
56. Podolsky, D.K., Inflammatory bowel disease. N Engl J Med 347 (2002), 417–429.
57. Zhou, Y., Xu, Z.Z., He, Y., et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems, 3, 2018.
58. Schirmer, M., Franzosa, E.A., Lloyd-Price, J., et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat Microbiol 3 (2018), 337–346.
59. Bennet, J.D., Brinkman, M., Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet, 1, 1989, 164.
60. Borody, T.J., Warren, E.F., Leis, S., et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37 (2003), 42–47.
61. Kump, P.K., Grochenig, H.P., Lackner, S., et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19 (2013), 2155–2165.
62. Damman, C.J., Brittnacher, M.J., Westerhoff, M., et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLoS One, 10, 2015, e0133925.
63. Suskind, D.L., Singh, N., Nielson, H., et al. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 60 (2015), 27–29.
64. Uygun, A., Ozturk, K., Demirci, H., et al. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine (Baltimore), 96, 2017, e6479.
65. Suskind, D.L., Brittnacher, M.J., Wahbeh, G., et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 21 (2015), 556–563.
66. Vaughn, B.P., Vatanen, T., Allegretti, J.R., et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease. Inflamm Bowel Dis 22 (2016), 2182–2190.
67. Vermeire, S., Joossens, M., Verbeke, K., et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis 10 (2016), 387–394.
68. Cui, B., Feng, Q., Wang, H., et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 30 (2015), 51–58.
69. He, Z., Li, P., Zhu, J., et al. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. Sci Rep, 7, 2017, 4753.
70. Kahn, S.A., Vachon, A., Rodriquez, D., et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis 19 (2013), 1506–1513.
71. Khanna, S., Vazquez-Baeza, Y., Gonzalez, A., et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome, 5, 2017, 55.
72. Rossen, N.G., Fuentes, S., van der Spek, M.J., et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149 (2015), 110–118.e4.
73. Moayyedi, P., Surette, M.G., Kim, P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149 (2015), 102–109.e6.
74. Paramsothy, S., Kamm, M.A., Kaakoush, N.O., et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389 (2017), 1218–1228.
75. Costello, S.P., Soo, W., Bryant, R.V., et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 46 (2017), 213–224.
76. Kump, P., Wurm, P., Grochenig, H.P., et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 47 (2018), 67–77.
77. Kennedy, P.J., Cryan, J.F., Dinan, T.G., et al. Irritable bowel syndrome: a microbiome-gut-brain axis disorder?. World J Gastroenterol 20 (2014), 14105–14125.
78. De Palma, G., Lynch, M.D., Lu, J., et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med, 9, 2017.
79. Andrews, P.J., Borody, T.J., “Putting back the bugs”: bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med J Aust 159 (1993), 633–634.
80. Kurokawa, S., Kishimoto, T., Mizuno, S., et al. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: an open-label observational study. J Affect Disord 235 (2018), 506–512.
81. Acharya, C., Sahingur, S.E., Bajaj, J.S., Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight, 2, 2017.
82. Chen, Y., Yang, F., Lu, H., et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54 (2011), 562–572.
83. Bajaj, J.S., Heuman, D.M., Hylemon, P.B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60 (2014), 940–947.
84. Fernandez, J., Tandon, P., Mensa, J., et al. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology 63 (2016), 2019–2031.
85. Chen, Y., Guo, J., Qian, G., et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol 30 (2015), 1429–1437.
86. Bajaj, J.S., Moreau, R., Kamath, P.S., et al. Acute-on-chronic liver failure: getting ready for prime-time. Hepatology, 2018 Epub ahead of print.
87. Philips, C.A., Pande, A., Shasthry, S.M., et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 15 (2017), 600–602.
88. Bajaj, J.S., Kassam, Z., Fagan, A., et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66 (2017), 1727–1738.